Rns Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rns pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rns Pharma Today - Breaking & Trending Today

NS-089/NCNP-02 Receives Orphan Drug Designation from the European Commission for the Treatment of Duchenne Muscular Dystrophy

/PRNewswire/ NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd., announced that, on December 13, 2023, the European Commission (EC) has. ....

Takeshi Seita , Nippon Shinyaku Co Ltd , Research Development , National Center , Prnewswire Ns Pharma Inc , European Commission , Ns Pharma Inc , European Union , Drug Administration , Vice President , Nippon Shinyaku , Duchenne Muscular Dystrophy , Rns Pharma ,

NS Pharma Unveils Duchenne Heroes, a Program to Inspire and Amplify the Voices of People Living with Duchenne Muscular Dystrophy

/PRNewswire/ NS Pharma, Inc. ("NS Pharma") today announced the launch of Duchenne Heroes a program created to raise awareness and champion the voices of. ....

Gilberto Gil , Brantley Duchenne , Elizabeth Cojeen , Duchenne Heroe , Dianna Marlow , Prnewswire Ns Pharma Inc , Ns Pharma Inc , Nippon Shinyaku Co Ltd , Duchenne Heroes , Caregiver Marketing , Duchenne Muscular Dystrophy , Nippon Shinyaku , Rns Pharma , Health Care Amp Hospitals , Computer Amp Electronics , Medical Pharmaceuticals , Multimedia Amp Internet , Corporate Social Responsibility , New Products Amp Services ,

NS-089/NCNP-02 Preclinical Data Published in Molecular Therapy Nucleic Acids

/PRNewswire/ NS Pharma, Inc. announced today the publication of preclinical data on NS-089/NCNP-02 (brogidirsen), an investigational candidate for patients. ....

United States , Kazuyuki Nakagome , Tsugio Tanaka , Toru Nakai , National Center , Ns Pharma Inc , Drug Administration , Nippon Shinyaku Co Ltd , Nippon Shinyaku , Molecular Therapy Nucleic , Kodaira City , Rare Pediatric Disease , Breakthrough Therapy , Orphan Drug Designations , Duchenne Muscular Dystrophy , Rns Pharma , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,

CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterates upcoming milestones. ....

United States , Jenene Thomas , John Climaco , Company On Twitter , Pharmaceuticals Inc , Shareholder Intelligence Services , Securities Exchange , Exchange Commission , Data Safety Monitoring Board , Expected Milestones , Potentially Pivotal Trial , Financial Results , Second Quarter , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , The Company , Clinical Trial , Interim Analysis , Rns Pharma , Pivotal Study ,

FDA Grants Rare Pediatric Disease Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy

/PRNewswire/ NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Rare Pediatric Disease Designation to NS-089/NCNP-02. ....

United States , Kazuyuki Nakagome , Toru Nakai , Tsugio Tanaka , Us Food Drug Administration , Ns Pharma Inc , Nippon Shinyaku Co Ltd , National Center , Nippon Shinyaku , Drug Administration , Rare Pediatric Disease Designation , Pediatric Disease Designation , Neurological Medicine , Kodaira City , Duchenne Muscular , Rns Pharma , Health Care Amp Hospitals , Medical Pharmaceuticals , Pharmaceuticals , Fda Approval ,